TABLE 3

PARP activity (mmol NAD+ per 30 min)* in cell-free system containing PARP and NAD+

CompoundConcentrations
010 nmol/l100 nmol/l1 μmol/l10 μmol/l100 μmol/l
300 μmol/l NAD+
Fidarestat0.327 ± 0.0060.307 ± 0.0030.292 ± 0.0170.312 ± 0.0040.300 ± 0.0030.301 ± 0.001
INO-10010.327 ± 0.0060.270 ± 0.0060.042 ± 0.00140.00125 ± 0.00030.0015 ± 0.0060.0015 ± 0.0003
850 μmol/l NAD+
Fidarestat0.315 ± 0.0060.306 ± 0.0030.308 ± 0.0090.300 ± 0.0060.309 ± 0.0100.288 ± 0.003
INO-10010.315 ± 0.0060.302 ± 0.0040.009 ± 0.0040.0043 ± 0.00060.0025 ± 0.0030.00125 ± 0.00025
  • Data are means ± SE (n = 4–7).

  • *

    * The potent PARP inhibitor INO-1001 was used as a positive control.